Research has produced synthetic THC, FDA approved for the treatment of nausea and wasting syndrome. Synthetic cannabinoids are a lot stronger than natural cannabinoids, they are isolated compounds, they do not contain full spectrum cannabinoids, they do not create the entourage effect and have never really had a high success rate within the medical community.
The first artificial cannabinoids were synthesized by Roger Adams within the early Nineteen Forties. Early cannabinoid analysis targeting consciousness-altering drug or "THC" because the main mind-blowing compound found within the cannabis plant.
Other natural cannabinoids like cannabidiol or "CBD" ar less well studied, and not ill-gotten in most jurisdictions.
Most synthetic cannabinoids are analogues of THC.
The first generation of THC analogues (synhexyl, nabilone, nabitan, nantradol) featured slight variations of the THC molecule, such as esterifying the phenolic hydroxy group, extending and branching of the pentyl side chain.
These analogs can be grouped into classical (HU-210), bicyclic (CP-55,940), and tricyclic (CP-55,244).
Tritium-labelled cannabinoids like [³H]CP-55,940 were instrumental in discovering the cannabinoid receptors within the early Nineteen Nineties.
Nabilone entered the clinic in 1981 as associate degree medication.
Synthetic psychoactive drug (marinol, dronabinol) entered the clinic in 1985 as associate degree medicationassociate degreed once more in 1991 as a craving stimulant.
The second generation of THC analogs features compounds derived from anandamide (metanandamide), aminoalkylindole (WIN 55,212-2), pyrrole, pyrazole (SR-141716A), and indene (BAY 38-7271).